Detalhe da pesquisa
1.
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Mult Scler
; 28(7): 1131-1137, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994577
2.
Profiling DNA damage-induced phosphorylation in budding yeast reveals diverse signaling networks.
Proc Natl Acad Sci U S A
; 113(26): E3667-75, 2016 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27298372
3.
Essential role of limiting telomeres in the pathogenesis of Werner syndrome.
Nat Genet
; 36(8): 877-82, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15235603
4.
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Mult Scler J Exp Transl Clin
; 9(2): 20552173231169463, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37139460
5.
Mrc1 phosphorylation in response to DNA replication stress is required for Mec1 accumulation at the stalled fork.
Proc Natl Acad Sci U S A
; 106(31): 12765-70, 2009 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-19515819
6.
Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon ß-1a phase 1 study.
Med
; 3(9): 612-621.e3, 2022 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853458
7.
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
Mult Scler Relat Disord
; 57: 103350, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158459
8.
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Mult Scler Relat Disord
; 57: 103367, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158473
9.
Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate.
Ther Adv Neurol Disord
; 14: 1756286420975916, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33488773
10.
Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach.
Neurol Ther
; 10(1): 251-263, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761099
11.
Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers.
Ther Adv Neurol Disord
; 14: 1756286420975227, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33628334
12.
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
CNS Drugs
; 35(3): 317-330, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743151
13.
DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse.
Mol Cell Biol
; 27(6): 2253-65, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17145779
14.
Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Mult Scler Relat Disord
; 40: 101954, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32078948
15.
RAD51-dependent break-induced replication differs in kinetics and checkpoint responses from RAD51-mediated gene conversion.
Mol Cell Biol
; 25(3): 933-44, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15657422
16.
Peginterferon ß-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.
Ther Adv Neurol Disord
; 11: 1756286418795085, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181780
17.
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.
Ther Adv Neurol Disord
; 11: 1756286418791143, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181778
18.
Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression.
Genes Dev
; 17(1): 88-100, 2003 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12514102